27th Annual EuroMeeting

Back to Agendas

PATIENT INVOLVEMENT IN THE DEVELOPMENT DIALOGUE WITH REGULATORY AUTHORITIES AND HTAS

Session Chair(s)

Isabelle Stoeckert, PharmD, PMP

VP. Head Regulatory Affairs Europe Middle East Africa PH

Bayer, Germany

Patient involvement in innovative drug development and access considerations is a hot topic, methodological work is rapidly evolving. The session provides insight into latest research of EMA and IMI PROTECT on patient value elicitation methodologies

Learning Objective : Aim of this session is to outline state of the art concepts how patients could be involved in medicinal product development and access to new therapies

Speaker(s)

How Can Regulatory Authorities and HTAs Build on Patient Input - the European Medicines Agency perspective

Francesco Pignatti, MD

European Medicines Agency, Netherlands

Scientific Adviser for Oncology

The Patient Perspective in Drug Development

François Houyez

European Organisation for Rare Diseases (EURORDIS), France

Treatment Information and Access Director, Health Policy Advisor

Patient and Public Involvement in Innovative Drug Development and Benefit/Risk Decision Making – what is state of the art after PROTECT WP5

Kimberley Hockley

Imperial College of Public Health, United Kingdom

Research Associate

Have an account?